As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

Accra, Nov 13, GNA – The Rebecca Foundation, has in partnership with the Merck Foundation, presented school supplies and personal items to some 30 brilliant but needy girl children in the Greater ...

Shares of Amgen and 3M are trading lower Tuesday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Amgen and 3M are contributing to the blue-chip gauge's intraday ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...

Ginkgo Bioworks (DNA) completed the first milestone of a partnership with Merck (MRK) focused on improving biologic manufacturing. As part of ...